Pfizer Aborts Japan And Global Phase 3 Non-Hodgkin’s Lymphoma Trials Of Inotuzumab Ozogamicin
This article was originally published in PharmAsia News
Executive Summary
Pfizer has aborted its joint international Phase III trials of inotuzumab ozogamicin for the treatment of non-Hodgkin’s lymphoma, the company announced May 22.